Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Diabetes
MicroTech’s LinX CGM Wins India Approval, Expanding Asia Diabetes Monitoring
MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM)...
Novo’s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First
Novo Nordisk A/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization...
Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced that the European Medicines Agency (EMA) has...
Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes
Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared...
Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart
Tonghua Dongbao Pharmaceuticals Co., Ltd. (SHA: 600867) announced that its Insulin Aspart Injection 3 ml : 300 IU pre‑filled...
Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026
Novo Nordisk A/S (NYSE: NVO) released an internal memorandum outlining a sweeping re‑organization of its...
Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...
Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...
HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...
Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...
Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
Hengrui Medicine (SHA: 600276, HKG: 1276) today announced the commercial launch of its first independently developed...
Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes
Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted...
Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...
Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline
Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator
China‑based Hua Medicine (HKG: 2552) announced that the Hong Kong Department of Health has accepted its...
Gan & Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced a landmark Technology Transfer and Supply...
MicroTech Medical Secures NMPA Approval for Equil Patch Insulin Pump in Children and Adolescents
MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that China’s National Medical Products Administration (NMPA)...